


# PRODUCT INFORMATION



## Methyl 5,6,7,8-Tetrahydro Risperidone

Item No. 17801

**CAS Registry No.:** 106266-08-4  
**Formal Name:** 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,7-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one  
**MF:** C<sub>24</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>2</sub>  
**FW:** 420.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 259, 285, 345 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Methyl 5,6,7,8-tetrahydro risperidone is supplied as a crystalline solid. A stock solution may be made by dissolving the methyl 5,6,7,8-tetrahydro risperidone in the solvent of choice, which should be purged with an inert gas. Methyl 5,6,7,8-tetrahydro risperidone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of methyl 5,6,7,8-tetrahydro risperidone in these solvents is approximately 0.25, 1, 0.1 mg/ml, respectively.

Methyl 5,6,7,8-tetrahydro risperidone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, methyl 5,6,7,8-tetrahydro risperidone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Methyl 5,6,7,8-tetrahydro risperidone has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Risperidone (Item No. 13629) is a benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.<sup>1,2</sup> Methyl 5,6,7,8-tetrahydro risperidone is used as an internal standard used in the quantitative analysis of risperidone.<sup>3,4</sup>

### References

1. Colpaert, F.C. Discovering risperidone: The LSD model of psychopathology. *Nat. Rev. Drug Discov.* **2**, 315-320 (2003).
2. Rainer, M.K. Risperidone long-acting injection: A review of its long term safety and efficacy. *Neuropsychiatr. Dis. Treat.* **4**(5), 919-927 (2008).
3. Janssen, P.A., Niemegeers, C.J., Awouters, F., et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S<sub>2</sub> and dopamine-D<sub>2</sub> antagonistic properties. *J. Pharmacol. Exp. Ther.* **244**, 685-693 (1988).
4. Gelders, Y.G., Heylen, S.L., Vanden Bussche, G., et al. Pilot clinical investigation of risperidone in the treatment of psychotic patients. *Pharmacopsychiatry* **23**, 206-211 (1990).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM